Hepatic Steatosis clinical trials
8 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
- Siemens Biomarker Multi-modality
- Hepatic Lipid Metabolism-Alcohol Use Disorder
- Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
- Liver Micro Flow - MRI
- Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hepatic Steatosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.